For the Inventor, By the Inventor

Enter assignee name

The Green Cross Corporation

USPTO Granted Patents = 260

CIPO Patents = 4

EPO Patents = 22

Trademarks = 2

Forward Citations = 2,956

Loading Chart...

Loading Chart...

543 inventors (with patents filed for the assignee):

Kazumasa Yokoyama (72 out of 80 patents)

Tadakazu Suyama (47 out of 47 patents)

Chikara Fukaya (33 out of 34 patents)

4. Satoshi Funakoshi (25 out of 25 patents)

5. Taizo Ono (24 out of 24 patents)

6. Takao Ohmura (21 out of 24 patents)

7. Yahiro Uemura (20 out of 25 patents)

8. Yoshio Arakawa (20 out of 20 patents)

9. Yoshihisa Inoue (18 out of 18 patents)

10. Yoshio Tsuda (18 out of 18 patents)

11. Hee Jeong Seo (14 out of 25 patents)

12. Youichiro Naito (14 out of 15 patents)

13. Suk Ho Lee (13 out of 31 patents)

14. Min Ju Kim (13 out of 20 patents)

15. Masahiro Watanabe (13 out of 16 patents)

Core Competencies:

Bispecific Antibodies

Anti-EGFR Antibodies

SGLT2 Inhibitors

Recombinant Human Iduronate-2-Sulfatase

Cancer Treatment

Hepatitis B Virus

Anemia Treatment

Tumor Specific Promoters

Immunoglobulin Purification

Pyrazole Derivatives

Depressive Disorders

Neuroprotective Properties

260 patents: Sort by Forward Citations

1. 12338237 - Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same (2025-06-24),

2. 12319746 - Bispecific antibody specifically binding to GPNMB and CD3, and use thereof (2025-06-03),

3. 12247082 - Highly efficient anti-TFPI antibody composition (2025-03-11),

4. 11584777 - Method for purifying a sulfatase protein (2023-02-21),

5. 11535646 - Method for purification of immunoglobulin (2022-12-27),

6. 11524054 - Method of treating anemia using long-acting EPO formulation (2022-12-13),

7. 11498965 - Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same (2022-11-15),

8. 11447559 - Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same (2022-09-20),

9. 11401343 - Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same (2022-08-02),

10. 11332528 - Anti-CEACAM1 antibody and use thereof (2022-05-17),

11. 11198733 - Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor (2021-12-14),

12. 11052135 - Methods and compositions for treating hunter syndrome (2021-07-06),

13. 10918717 - Pharmaceutical formulation comprising anti-EGFR antibody (2021-02-16),

14. 10889574 - Method for producing diphenylmethane derivative (2021-01-12),

15. 10851175 - Anti-mesothelin antibody and composition comprising the same (2020-12-01),

The Green Cross Corporation is a leading sustainable and eco-friendly company that specializes in the production and distribution of organic and natural products. With a commitment to environmental stewardship, the company offers a wide range of innovative solutions for sustainable living and green technologies. The Green Cross Corporation aims to make a positive impact on society by promoting a greener lifestyle and providing high-quality, environmentally friendly products.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

260 Patents

#63 in Osaka

#567 in Japan

#3,246 in the World

The Green Cross Corporation

Forward Citations = 2,956

543 inventors:

Kazumasa Yokoyama (72 out of 80 patents)

Tadakazu Suyama (47 out of 47 patents)

Chikara Fukaya (33 out of 34 patents)

4. Satoshi Funakoshi (25 out of 25 patents)

5. Taizo Ono (24 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…